Quebec

General contact information for trials in Quebec:

Montreal:

  • qcroc.ca/etudes-en-cours
  • Julie Frémond, Trials Coordinator, Centre Hospitalier Universitaire de Montreal (514-890-8000 x30831, jfremond@qcroc.ca)
  • Dr. Rejean Lapointe, Chair of Cancer Research at the Centre Hospitalier Universitaire de Montreal (514-890-8000, Ext. 25489, rejean.lapointe@umontreal.ca)
  • Dr. Wilson Miller, Director of Clinical Oncology at the Jewish Hospital of Montreal (514-840-8222, Ext. 4365, wmiller@ldi.jgh.mcgill.ca)
  • Leila Idrissi, Research Coordinator, Maisonneuve-Rosemont Hospital (leila.idrissi.kaitouni.cemtl@ssss.gouv.qc.ca)

Sherbrooke:

Quebec:

  • qcroc.ca/etudes-en-cours
  • Hugo Garneau (Oncology Research coordinator, Centre de recherche de CHU de Quebec-Universite-Laval), 418-525-4444 x47444, hgarneau@qcroc.ca
  • Jacques Côté (Director of Oncology Research, Centre Hospitalier Universitaire de Quebec) – 1-418-525-4444

Current trials:

VOYAGER Trial

Recruiting locations in Quebec:

  • Jewish General Hospital (Dr. Petr Kavan: 514-340-8222, Ext. 4210; Inna Zhylina: 514-340-8222, Ext. 28437)

ID Number: NCT03465722

Links:

Description: This study looks at the drug Avapritnib (BLU-285) for patients with advanced or metastatic a Gastrointestinal Stromal Tumor (GIST) compared to Regorafenib. Patients will take one of the two study drugs over 2 months and the researchers will compare their survival and disease status over time to decide which medication is more effective.

  • Group A will receive Avapritnib.
  • Group B will receive a Regorafenib.

Intervention: Both of the drugs being compared in this study are meant to stop cancer cells from spreading. Regorafenib is a kinase inhibitor. This means that it stops cancer cells from producing certain proteins they need to survive and divide. It is widely used to treat various types of cancer. Avapritnib looks like a promising new treatment which can stop cancer cells from dividing. This trial will help to figure out if it is helpful in treating a specific type of gastric cancer.

Can I consider participating?

  • Yes: adult patients with an unresectable GIST who have already been treated with a medication called imatinib, as well as 1-2 other medications which are tyrosine kinase inhibitors (TKIs)
  • No: patients who have been treated with Avapritnib or Regorafenib in the past; patients who have tried 3 or more TKI medications in the past

TOPGEAR Trial

Recruiting locations in Quebec:

  • Montreal – Nouveau Centre Hospitalier Universitaire de Montreal (Dr Moishe Liberman, MD, Julie Frémond, 514-890-8000 x30831, jfremond@qcroc.ca)
  • Montreal – Jewish Central Hospital (Dr Petr Kavan, MD: 514-340-8222 Ext. 4210)
  • Montreal – Maisonneuve-Rosemont Hospital (Dr. Cathy Menkarios, Veronique Tang, 514-549-9155)

ID Number: NCT01924819

Links:

Description: This study is trying to understand the best way to treat patients with resectable gastric cancer before their surgery. The researchers want to see if chemotherapy with radiation (chemoradiotherapy) is more helpful than just chemotherapy before surgery.  There will be two groups compared in this experiment:

  • Group A – will have chemotherapy + chemoradiotherapy before surgery.
  • Group B – will have only chemotherapy before surgery.

All patients in this study will be having a gastrectomy and a D1 lymphadenectomy. Then, all patients will have chemotherapy after surgery. The researchers will be looking at overall survival in the two groups over time. The estimated end date for the study is December, 2020.

Intervention:

  • Group A: chemotherapy (epirubicin, cisplatin, fluorouracil) with radiation before surgery, and chemotherapy after surgery
  • Group B: chemotherapy (epirubicin, cisplatin, fluorouracil) before surgery and after surgery

Can I consider participating?

  • Yes: patients who have stage 1B gastric or gastroesophageal tumor which is considered resectable by a surgeon.
  • No: people who have had chemotherapy or radiotherapy before, advanced gastric tumors, metastatic gastric cancer

Keynote-585 Trial

Recruiting locations in Quebec:

  • Sherbrooke – Centre Hospitalier universitaire de Sherbrooke (Dr Frédéric Lemay, MD: 819-346-1110)
  • Montreal – Jewish Central Hospital (Dr Petr Kavan, MD: 514-340-8222 Ext. 4210)
  • Montreal – Maisonneuve Hospital (Dr. Mai-Kim Gervais, 418-525-4444, Ext. 22644)
  • Greenfield Park – Hopital Charles LeMoyne (Dr. Nathalie Daaboul: 450-466-5065)

ID Number: NCT03221426

Links:

Description: This study will be looking at the effects of the drug Pembrolizumab as part of pre-surgical treatment. The drug will be given before and after gastric cancer surgery with different chemotherapy routines. This study will be comparing two things. First, Pembrolizumab with chemotherapy will be compared to a placebo with chemotherapy. This is done to determine if it is helpful in general. Next, Pembrolizumab given with systemic chemotherapy will be compared to Pembrolizumab given with FLOT chemotherapy. FLOT is a commonly prescribed chemotherapy routine for gastric cancer patients. There will be four groups in this experiment:

  • Group A – Pembrolizumab and systemic chemotherapy
  • Group B – placebo and systemic chemotherapy
  • Group C – Pembrolizumab and FLOT chemotherapy
  • Group D – placebo and FLOT chemotherapy

The researchers think that this drug can improve outcomes for patients, by increasing overall survival and event-free survival. This means patients will live longer without a recurrence of cancer.

Intervention:

  • Pembrolizumab: Sometimes, cancer cells stop our immune system from recognizing the growth of a tumor.  This way, the cancer is effectively able to “hide” from our body’s defense mechanisms. Pembrolizumab reverses this effect of the cancer cells so they can be detected and fought off by our body.
  • Systemic Chemotherapy: Cisplatin and Capecitabine/5-Fluorouracil
  • FLOT: Docetaxel, Oxaliplatin, 5-Fluorouracil and Leucovorin

Can I consider participating?

  • Yes: patients with a T3 gastric tumor and some cancerous lymph nodes, but no metastases. Have never been treated before and are planning on having surgery.
  • No: patients who are not eligible for surgery (e.g.: metastatic disease), have ever had pneumonitis, have a current infection, have ever had treatment with other immune or cancer therapies (chemo/radiation)

OPDIVO Trial

Recruiting locations in Quebec:

  • Quebec – L’Hotel-Dieu de Quebec (Dr Félix Couture, MD: 418-691-2950)
  • Trois Rivieres – Centre Hospitalier regional (Dr Jean-Sébastien Aucoin, MD: 819-697-3333)
  • Montreal – Jewish General Hospital and Montreal General Hospital (Dr Thierry Alcindor, MD: 514-934-1934 Ext. 43118)

ID Number: NCT02743494

Links:

Description: This study looks at the drug nivolumab for patients with advanced gastric cancer who have had surgery. The experiment will compare the survival of two patient groups after surgery:

  • Group A will receive Nivolumab.
  • Group B will receive a placebo instead.  

Intervention: Sometimes, cancer cells stop our immune system from recognizing the growth of a tumor.  This way, the cancer is effectively able to “hide” from our body’s immune defense mechanisms. Nivolumab is a drug which helps your immune system (T cells) find and attack cancerous cells. This means that it is a type of immunotherapy drug.

Can I consider participating?

  • Yes: patients who already had chemoradiotherapy and surgery for stage 2 or 3 esophageal or gastroesophageal cancer, however the disease is still present
  • No: patients who have stage 4 cancer, or did not have chemoradiotherapy before surgery

CheckMate649 Trial

Recruiting locations in Quebec:

  • Montreal – Centre Hospitalier universitaire de Montreal (Dr Mustapha Tehfé, MD: 514-890-8000 Ext. 25106)
  • Montreal – Jewish General Hospital (Dr Petr Kavan, MD: 514-340-8222 Ext. 4210)

ID Number: NCT02872116

Link:

Description: This trial is looking to better understand the immunotherapy drug Nivolumab. They want to know if Nivolumab is helpful, and which chemotherapy routine is best to pair it with. To figure this out, there will be five groups in this trial:

  • Group A – Nivolumab and Ipilimumab
  • Group B – Nivolumab and XELOX (oxaliplatin and capecitabine)
  • Group C – Nivolumab and FOLFOX (oxaliplatin, leucovorin and fluorouracil)
  • Group D – XELOX only (oxaliplatin and capecitabine)
  • Group E – FOLFOX only (oxaliplatin, leucovorin and fluorouracil)

Intervention: Nivolumab is a drug that helps your immune system (T cells) attack cancerous cells. It is a type of immunotherapy drug. Ipilimumab is also a immunotherapy drug. XELOX and FOLFOX are both chemotherapy routines which are commonly prescribed for gastric cancer patients.

Can I consider participating?

  • Yes: patients who have advanced gastric cancer, have not received treatment within the last 6 months, able to provide a tumor biopsy sample
  • No: patients who have cancer of the brain or spinal cord, autoimmune disease, or a current infection

JAVELIN-Medley Trial

Recruiting location in Quebec:

  • Montreal – Nouveau Centre Hospitalier universitaire de Montreal (Dr. Rahima Jamal: 514-890-8000, Ext. 8444)

ID Number: NCT02554812

Link:

Description: This is a Phase II trial. It is looking at the effects of the drug Avelumab combined with other cancer therapies for treating advanced gastric tumors. There are many treatment groups in this trial, because the researchers are interested in testing various dosages of each drug, as well as different combinations. The drug combinations they will be testing are:

  • A: Avelumab and Utomilumab
  • B: Avelumab and PF-04518600
  • C: Avelumab and PD-0360324
  • D: Avelumab, Utomilumab and PF-04518600

Intervention: All of the medications involved in this trial are immunotherapeutic. They help our immune system’s T cells recognize and attack tumor cells. This trial is trying to understand the effects of the drugs in combination with each other, as well as determine the appropriate dose for each medication.

Can I consider participating?

  • Yes: patients with an advanced gastric tumor who have a life expectancy of at least 3 months. The tumor has not been treated with radiation or systemic chemotherapy within 1 year.
  • No: patients who are currently having immunotherapy, recently had surgery (within 4 weeks), current infection

TREMELIMUMAB/MEDI4736 Trial

Recruiting location in Quebec:

  • Montreal – contact AstraZeneca Cancer Study Locator Service (1-8777-400-4656, AstraZeneca@emergingmed.com) for site specific details and enrolment information

ID Number: NCT02340975

Link:

Description: This is a Phase II trial. The researchers are trying to understand what the best dose of the drug MEDI4736 is for patients with metastatic or recurrent gastric cancer. This drug will be tested in combination with an immunotherapy medication called tremelimumab. There are five groups in this study:

  • Group A: MEDI4736 and Tremelimumab (dose 1)
  • Group B: MEDI4736 only
  • Group C: Tremelimumab only
  • Group D: MEDI4736 and Tremelimumab (dose 2)
  • Group E: MEDI4736 and Tremelimumab (dose 3)

Groups D and E are “third line” patients. This means that the original (first/second line) treatment they were receiving before did not work, or stopped working. Group E is consists only of patients who express specific biomarkers (for example: a certain protein) on the surface of their cells.

Intervention: MEDI4736 and Tremelimumab are both immunotherapeutic drugs. They work to help our body’s T cells find and destroy cancer cells.

Can I consider participating?

  • Yes: patients who have metastatic or recurrent gastric or gastroesophageal cancer, those who have tried other chemotherapy and treatments in the past which have not worked, must be able to provide a tumor biopsy
  • No: patients currently having chemotherapy, hormonal therapy or radiotherapy, patients who have had immunotherapeutic treatment for their cancer in the past